Jmac Enterprises LLC Sells 4,042 Shares of Pfizer Inc. $PFE

Jmac Enterprises LLC lessened its holdings in Pfizer Inc. (NYSE:PFE) by 25.4% during the second quarter, HoldingsChannel.com reports. The firm owned 11,872 shares of the biopharmaceutical company’s stock after selling 4,042 shares during the period. Jmac Enterprises LLC’s holdings in Pfizer were worth $288,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the business. J. Safra Sarasin Holding AG lifted its position in shares of Pfizer by 22.7% in the second quarter. J. Safra Sarasin Holding AG now owns 143,246 shares of the biopharmaceutical company’s stock worth $3,472,000 after purchasing an additional 26,463 shares in the last quarter. ASR Vermogensbeheer N.V. raised its position in Pfizer by 1.9% during the second quarter. ASR Vermogensbeheer N.V. now owns 609,397 shares of the biopharmaceutical company’s stock worth $14,771,000 after acquiring an additional 11,443 shares in the last quarter. DMKC Advisory Services LLC raised its position in Pfizer by 18.3% during the second quarter. DMKC Advisory Services LLC now owns 69,020 shares of the biopharmaceutical company’s stock worth $1,697,000 after acquiring an additional 10,679 shares in the last quarter. Cliftonlarsonallen Wealth Advisors LLC raised its position in Pfizer by 7.7% during the second quarter. Cliftonlarsonallen Wealth Advisors LLC now owns 13,518 shares of the biopharmaceutical company’s stock worth $328,000 after acquiring an additional 968 shares in the last quarter. Finally, CHURCHILL MANAGEMENT Corp raised its position in Pfizer by 13.5% during the second quarter. CHURCHILL MANAGEMENT Corp now owns 371,083 shares of the biopharmaceutical company’s stock worth $8,995,000 after acquiring an additional 44,218 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Trading Down 0.5%

PFE stock opened at $27.08 on Friday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The company’s 50-day simple moving average is $24.62 and its 200 day simple moving average is $24.14. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $30.43. The company has a market capitalization of $153.94 billion, a PE ratio of 14.40, a price-to-earnings-growth ratio of 0.88 and a beta of 0.55.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. During the same period in the prior year, the company posted $0.60 earnings per share. Pfizer’s revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Analysts Set New Price Targets

PFE has been the topic of several analyst reports. Morgan Stanley upped their price target on shares of Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 6th. Citigroup upped their price target on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Bank of America upped their price target on shares of Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. UBS Group reaffirmed a “neutral” rating and set a $28.00 price target on shares of Pfizer in a research report on Wednesday. Finally, Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $28.29.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.